Abstract
Rucaparib is a potent inhibitor of poly (ADP-ribose) polymerase (PARP) PARP1, PARP2 and PARP3, and to a lesser extent, PARP4, PARP10, PARP12, PARP15 and PARP16. Study 10 and ARIEL2 evaluated the use of rucaparib as treatment in patients with recurrent high-grade ovarian carcinoma and resulting in approval of rucaparib for patients with both germline and somatic BRCA mutation. Data from the Phase III trial ARIEL3 led to approval in platinum-sensitive disease as maintenance. This article reviews the efficacy, safety, pharmacokinetics and pharmacodynamics of rucaparib as well as future and ongoing trials.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 3101-3110 |
| Number of pages | 10 |
| Journal | Future Oncology |
| Volume | 14 |
| Issue number | 30 |
| DOIs | |
| State | Published - Dec 2018 |
Keywords
- BRCA mutated ovarian cancer
- Company tests
- Ovarian cancer
- Ovarian cancer maintenance treatment
- PARP
- Platinum sensitive ovarian cancer
- Poly (ADP-ribose) polymerase inhibitors
- Rucaparib
ASJC Scopus subject areas
- Oncology
- Cancer Research